Opportunity
Simpler Grants.gov #PAR-26-091
NCI Solicitation for Validation of Cancer Biomarkers and Assays (UH2/UH3)
Buyer
National Institutes of Health
Posted
December 08, 2025
Respond By
February 08, 2027
Identifier
PAR-26-091
NAICS
541714, 541715, 541380
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is inviting applications for research funding to validate cancer biomarkers and assays. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Scope of Work: - Validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of treatment response or resistance - Includes validation of pharmacodynamic and toxicity markers - Supports both analytical validation (UH2 phase) and clinical validation (UH3 phase) using biospecimens from clinical trials or studies - Encourages harmonization of clinical laboratory tests across multiple laboratories - Products/Services Requested: - No specific OEMs, vendors, products, or part numbers are listed - Focus is on research and development projects for assay and biomarker validation - Unique Requirements: - Open to a wide range of eligible applicants, including government entities, nonprofits, businesses, and educational institutions - Emphasis on advancing clinically validated assays for use in cancer studies and trials
Description
The National Cancer Institute (NCI) is soliciting applications to support the validation of molecular, cellular, and imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of treatment response or resistance. Applicants may submit either a biphasic UH2/UH3 application for 5 years or a standalone UH3 application for 3 years to support clinical validation of established assays. The UH2 phase supports analytical validation of assays within 2 years, followed by the UH3 phase for clinical validation using well-annotated biospecimens. The NOFO also supports validation of pharmacodynamic markers and toxicity markers, with a focus on assays applicable to clinical trials, observational studies, or population studies.